Pharmaceutical compositions containing vanoxerine
Disclosed embodiments are related to compositions of vanoxerine (GBR 12909), including compositions of vanoxerine and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.
1 . A pharmaceutical composition in unit dosage form comprising vanoxerine, in an amount of from about 20-50% of the composition by weight; a diluent in an amount of from about 30-60% of the composition by weight; a binder in an amount of from about 15-25% of the composition by weight; a disintegrant in an amount of from about 1-5% of the composition by weight; a flowing agent from about 0.2-0.4% of the composition by weight; and a lubricant from about 0.2-0.4% of the composition by weight.
2 . The pharmaceutical composition of claim 1 , wherein said diluent is lactose monohydrate.
3 . The pharmaceutical composition of claim 1 , wherein said binder is microcrystalline cellulose.
4 . The pharmaceutical composition of claim 1 , wherein said disintegrant is cross-linked sodium carboxymethylcellulose.
5 . The pharmaceutical composition of claim 1 , wherein said flowing agent is colloidal silicon dioxide.
6 . The pharmaceutical composition of claim 1 , wherein said lubricant is magnesium stearate.
7 . The pharmaceutical composition of claim 1 , wherein said vanoxerine is present in an amount of from about 30-35% by weight of the composition.
8 . The pharmaceutical composition of claim 2 , wherein said lactose monohydrate is present in an amount of from 40-45% by weight of the composition.
9 . The pharmaceutical composition of claim 3 , wherein said microcrystalline cellulose is present in an amount of from 15-20% by weight of the composition
10 . The pharmaceutical composition of claim 4 , wherein said cross-linked sodium carboxymethylcellulose is present in an amount of from 1-3% by weight of the composition.
11 . The pharmaceutical composition of claim 5 , wherein said colloidal silicon dioxide is present in an amount of from 0.2-0.4% by weight of the composition.
12 . The pharmaceutical composition of claim 6 , wherein said magnesium stearate is present in an amount of from 0.2-0.4% by weight of the composition.
13 . The pharmaceutical composition of claim 1 , wherein said unit dosage form is a capsule.
14 . The pharmaceutical composition of claim 1 , wherein said unit dosage form is a tablet.